Drug Search Results
More Filters [+]

Bunazosin

Alternative Names: bunazosin
Latest Update: 2023-11-01
Latest Update Note: PubMed Publication

Product Description

Bunazosin, a selective alpha1-adrenoceptor antagonist, an anti-glaucoma drug (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15867947/)

Mechanisms of Action: ADRA1A Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Germany | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bunazosin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hypertension

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DTR-886-401

P4

Completed

Hypertension

2008-09-01

Recent News Events